anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Infections are a major cause of morbidity and mortality in cirrhosis, especially those caused by multi-drug resistant bacteria. During the COVID-19 pandemic, the incidence and type of infection in these patients may have been influenced by the restrictive measures implemented. We aimed to compare the infections in patients with cirrhosis hospitalized before the COVID-19 pandemic versus those hospitalized during the pandemic. We retrospectively compared infections in patients with cirrhosis hospitalized in the hepatology unit during the pre-pandemic period (3/2019-2/2020) with infections in patients hospitalized during the pandemic (3/2020-2/2021). Baseline characteristics, type of infections, type of bacteria, antimicrobial resistance and mortality were evaluated. There were 251 hospitalizations in 170 patients during the pre-pandemic period and 169 hospitalizations in 114 patients during the pandemic period. One or more infections were identified in 40.6% of hospitalizations during the pre-pandemic period and 43.8% of hospitalizations during the pandemic, P = 0.52. We found 131 infections in the pre-pandemic period and 75 infections during the pandemic. The percentage of nosocomial infections decreased in the pandemic period (25.3% vs. 37.4% in the pre-pandemic period, P = 0.06). We found a non-significant trend to a higher incidence of infections by multi-drug resistant organisms (MDRO) in the pandemic period than in the pre-pandemic period (6.5% vs. 4%). The incidence of infections was similar in both periods. However, during the pandemic, we observed a trend to a lower incidence of nosocomial infections with a higher incidence of MDRO infections.
Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
Polymyositis, dermatomyositis and related disorders, also known as the idiopathic inflammatory myopathies (IIM), are an uncommon, heterogeneous group of diseases. This is an omnibus protocol designed to continue our description of this rare group of diseases, further delineate important groups of patients, and obtain useful material for further study of immunological abnormalities, pathogenesis and etiology of IIM. Often the diagnosis of an IIM can be confused with other illness (such as adult-onset dystrophies), and therefore, we will be evaluating patients with other illnesses (who are referred with a preliminary diagnosis of an IIM) (1). Patients evaluated with IIM will receive (with informed consent) the best standard therapies available and consideration for entry into any therapeutic protocols. MRI will be performed on healthy volunteers to help develop a mathematical method for quantitating edema of muscle MRI in patients (2). MRI/PET will be performed on some patients and on healthy volunteers to evaluate its role in understanding muscle disease.
The invention discloses a purpose of electrostatic spinning fiber. The purpose belongs to application of delivery of anti-HIV (Human Immunodeficiency Virus) medicine for treating semen-caused infection to the vagina. CAP electrostatic spinning fiber is prepared, and the potential usability of the CAP electrostatic spinning fiber in the anti-HIV infection is shown. The CAP fiber does not have the toxicity on vaginal epithelial cells and vaginal lactobacilli on the vagina even after being dissolved. The result data further shows that the CAP fiber can maintain the completeness in an SVF, and can be fast dissolved in low-dosage semen. The CAP fiber can be easily combined with anti-HIV medicine (TMC 125 and Viread); and the HIV-1 spreading prevention possibility of the CAP fiber in the sexual intercourse process is improved.
Avian influenza, particularly the H9N2 subtype, presents significant challenges to poultry health, underscoring the need for effective antiviral interventions. This study explores the antiviral capabilities of Belamcanda extract, a traditional Chinese medicinal herb, against H9N2 Avian influenza virus (AIV) in specific pathogen-free (SPF) chicks. Through a comprehensive approach, we evaluated the impact of the extract on cytokine modulation and crucial immunological signaling pathways, essential for understanding the host-virus interaction. Our findings demonstrate that Belamcanda extract significantly modulates the expression of key inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-6 (IL-6), which are pivotal to the host's response to H9N2 AIV infection. Western blot analysis further revealed that the extract markedly reduces the expression of critical immune signaling molecules such as toll-like receptor 3 (TLR3), TIR-domain-containing adapter-inducing interferon-β (TRIF), and nuclear factor kappa B (NF-κB). These insights into the mechanisms by which Belamcanda extract influences host immune responses and hinders viral replication highlight its potential as an innovative antiviral agent for poultry health management. The study advances our comprehension of natural compounds' antiviral mechanisms and lays the groundwork for developing strategies to manage viral infections in poultry. The demonstrated ability of Belamcanda extract to modulate immune responses and inhibit viral replication establishes it as a promising candidate for future antiviral therapy development, especially in light of the need for effective treatments against evolving influenza virus strains and the critical demand for enhanced poultry health management strategies.
Impella and intra-aortic balloon pumps (IABP) are commonly utilized in patients with cardiogenic shock. However, the effect on mortality remains controversial. The goal of this study was to evaluate the effect of Impella and IABP on mortality in patients with cardiogenic shock the large Nationwide Inpatient Sample (NIS) database was utilized to study any association between the use of IABP or Impella on outcome. ICD-10 codes for Impella, IABP, and cardiogenic shock for available years 2016-2020 were utilized. A total of 844,020 patients had a diagnosis of cardiogenic shock. A total of 101,870 patients were treated with IABP and 39645 with an Impella. Total inpatient mortality without any device was 34.2% vs only 25.1% with IABP use (OR = 0.65, CI 0.62-0.67) but was highest at 40.7% with Impella utilization (OR = 1.32, CI 1.26-1.39). After adjusting for 47 variables, Impella utilization remained associated with the highest mortality (OR: 1.33, CI 1.25-1.41, p < 0.001), whereas IABP remained associated with the lowest mortality (OR: 0.69, CI 0.66-0.72, p < 0.001). Separating rural vs teaching hospitals revealed similar findings. In patients with cardiogenic shock, the use of Impella was associated with the highest whereas IABP was associated with the lowest in-hospital mortality regardless of comorbid condition.
PURPOSE:To realize rejuvenation and life-prolongation of aged person, by extracting juvenile cell of a man of embryo period, infant or younger generation from every part of the body and injecting or transplanting the cell to the corresponding parts of the parent of the donor of the juvenile cell. CONSTITUTION:Juvenile cells of a man of embryo period, infant or about <=20 years old are extracted from every part of the body. The extracted cells or their cultured cells are injected or transplanted to the corresponding parts of a parent of the donor of the juvenile cell. Prior to the injection or transplantation, half of the blood of the parent is exchanged with that of the child when they have the same blood type or half of the plasma of the parent is exchanged with that of the child when they have different blood type. The rejuvenation and life-prolongation of the parent can be carried out by this process suppressing the rejection reaction. If necessary, an immuno-suppressing agent such as cyclosporin is used in the above treatment. In the case of transplantation to grandfather or grandmother of donor, 3/4 of the plasma are uniformly exchanged among 4 grandfathers and grandmothers on the father's side and mother's side and optionally an immuno-suppressing agent is used to suppress the rejection reaction.
Difenoconazole (DFZ) is a fungicidal pesticide extensively employed for the management of fungal diseases in fruits, vegetables, and cereal crops. However, its potential environmental impact cannot be ignored, as DFZ accumulation is able to lead to aquatic environment pollution and harm to non-target organisms. Quercetin (QUE), a flavonoid abundant in fruits and vegetables, possesses antioxidant and anti-inflammatory properties. In this article, carp were exposed to 400 mg/kg QUE and/or 0.3906 mg/L DFZ for 30 d to investigate the effect of QUE on DFZ-induced respiratory toxicity in carp. Research shows that DFZ exposure increases reactive oxygen species (ROS) production in the carp's respiratory system, leading to oxidative stress, inflammation, and damage to gill tissue and tight junction proteins. Further research demonstrates that DFZ induces mitochondrial dynamic imbalance and gill cell apoptosis. Notably, QUE treatment significantly reduces ROS levels, alleviates oxidative stress and inflammation, and mitigates mitochondrial dynamics imbalance and mitochondrial apoptosis. This study emphasizes the profound mechanism of DFZ toxicity to the respiratory system of common carp and the beneficial role of QUE in mitigating DFZ toxicity. These findings contribute to a better understanding of pesticide risk assessment in aquatic systems and provide new insights into strategies to reduce their toxicity.
Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
PURPOSE:A foamable composition for the oral cavity especially preventing clogging during jetting, obtained by filling an aerosal propellant with a paste consisting of an abrasive, cellulose type binder, viscosity builder, activator, and water as main ingredients, and an aerosol propellant. CONSTITUTION:A paste consisting of an abrasive, cellulose type binder, viscosity builder, activator, and water as main ingredients, having viscosity preferably 20- 400 poise, is prepared. An aerosol container is filled with the paste and an aerosol propellant (preferably carbon dioxide gas) vaporizing at normal temperature under normal pressure, to give a composition for the oral cavity which is jetted and foamed in use. An alkali metal salt of carboxymethylcellulose having an average polymerization degree 50-300 and average esterification degree 0.4-1.0 is preferable as the binder. The use of the cellulose type binder as the binder characteristically prevents the clogging of the aerosol container. The composition is useful as a toothpaste, mouthwash agent, etc.
It is particularly important to administer bupropion hydrochloride extended-release tablets (XL) in a manner most likely to minimize the risk of seizure (see WARNINGS). Gradual escalation in dosage is also important if agitation, motor restlessness, and insomnia, often seen during the initial days of treatment, are to be minimized. If necessary, these effects may be managed by temporary reduction of dose or the short-term administration of an intermediate to long-acting sedative hypnotic. A sedative hypnotic usually is not required beyond the first week of treatment. Insomnia may also be minimized by avoiding bedtime doses. If distressing, untoward effects supervene, dose escalation should be stopped. Bupropion hydrochloride extended-release tablets (XL) should be swallowed whole and not crushed, divided, or chewed, as this may lead to increased risk of adverse effects including seizures. 

Bupropion hydrochloride extended-release tablets (XL) may be taken without regard to meals.
A method, a computing system and a computer program product are provided. A computing system identifies elements within a collection of medical documents. The elements include patients, adverse events and medical drugs. The medical documents are analyzed by the computer system to determine associations between the identified medical drugs and corresponding identified adverse events. The identified elements and the determined associations may be encoded as features by the computing system. The computing system identifies portions of the medical documents as containing the identified elements and the determined associations. The computing system generates a classification model based at least on the encoded features associated with the identified portions for identifying medical case safety reports within medical documents. The classification model is applied to a new document to determine a classification of the new document with respect to a medical case safety report.
Cadmium (Cd) is an accumulative toxic metal which poses a serious threat to human health, even in trace amounts. One of the most important steps in the pathophysiology of lung cancer (LC) is the epithelial-mesenchymal transition (EMT). In this investigation, a cell malignant transformation model was established by exposing human bronchial epithelial cells (16HBE) to a low dose of Cd for 30 weeks, after which a highly expressed circular RNA (circ_000999) was identified. Cd-induced EMT was clearly observed in rat lungs and 16HBE cells, which was further enhanced following circ_000999-overexpression. Furthermore, upregulated EIF4A3 interacted with the parental gene AGTPBP1 to promote high expression of circ_000999. Subsequent experiments confirmed that circ_000999 could regulate the EMT process by competitively binding miR-205-5p and inhibiting its activity, consequently upregulating expression of zinc finger E-box binding protein 1 (ZEB1). Importantly, the circ_000999 expression level in LC tissues was significantly increased, exhibiting a strong correlation with EMT indicators. Overall, these findings provide a new objective and research direction for reversing lung EMT and subsequent treatment and prevention of LC.
PURPOSE:To provide a hair cosmetic containing a polyoxyethylene polyoxypropylene glyceryl ether as an essential ingredient and, if necessary, a polyhydric alcohol in a specific ratio and having a hot touch. CONSTITUTION:A hair cosmetic having a hot touch is characterized by compounding a polyoxypropylene glyceryl ether of the formula (x, y are integers of 11) (especially preferably, x is 10-100; y is 5-50) in an amount of 30wt.% based on the whole amount of the cosmetic and water in an amount of <=30wt.%. The cosmetic may further be compounded with a polybasic alcohol having a mol. wt. of 50-600 in an amount of >=30wt.% based on the compound of the formula. The polyhydric alcohol is especially preferably polyethylene glycol 200, polyethylene glycol 300, the same 400, the same 600, propylene glycol or diglycerol. The cosmetic can have a thermal action, have an action to enhance the effects of hair cosmetics such as hair care products and scalp care products, and can simply be used.
Patients receive veliparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial.
The history of nasal polyposis originates even before Hippocrates described a nasal mass that he likened to a sea polyp. References to sinonasal disease and treatment can be found in ancient texts, such as the Ebers Papyrus and the Edwin Smith Papyrus of Ancient Egypt, as well as in the foundational texts of Ayurvedic medicine. Greek philosophers marked a significant shift away from the belief that illness was a result of divine intervention and embraced medical theory. Over the subsequent millennia, the understanding of nasal polyposis expanded, resulting in notable progress in surgical procedures and medical treatments. However, the complex pathophysiology of this condition remained enigmatic until breakthroughs in basic science and immunology. This historical journey takes us from the tomb of the first rhinologist in 2500 BC to the development of immune-modulating biologics.
Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
PURPOSE:To provide the titled imidazole-coordinated hem complex composed of an imidazole derivative having a specific substituent group at the 1-N atom and hem bonded with the 3-N atom through a coordinate bond, having low toxicity, good biocompatibility, and capable of keeping the gas absorbability even in an aqueous solution. CONSTITUTION:For example, the halide of formula X-A-B [X is halogen; A is -(CH2)n- or -SO2- (n is 0-3); B is 1-10C hydrocarbon group] is bonded to an imidazole compound of formula I (R<1> is methyl; R<2> and R<3> are H or methyl) by the dehydrohalogenation reaction. The resultant imidazole derivative of formula II (e.g. 1-phenetyl-2-methylimidazole) is mixed with an aqueous solution of cyclodextrin, and dried. The included imidazole can be obtained by removing the free imidazole from the dried product with a solvent. The included compound is mixed with hem [e.g. a complex of porphyrin and Fe(II)] in a solvent to obtain the objective complex.
A single resource in the form of a data bus (BS) is shared among a number of users in the form of Modules (M). Control of the bus is restricted to not more than one module at a time. Each module is assigned a different n-digit binary identity number, all the identity numbers containing the same number m of ones, and associated with BS there are n lines AB which perform the wired-OR function. When a request for the control of BS is made, the module or modules determines whether the resulting number carried by AB contains exactly m, or more than m, ones. If it contains more than m ones, indicating two or more requestors, arbitration between them takes place in a known manner to determine which of them shall control BS first. But if the number on AB contains exactly m ones there can be only one requestor and so arbitration is disposed-with.
These were a randomized, double-blind, multicenter, placebo-controlled studies that compared the efficacy and safety of 2.5% imiquimod cream and 3.75% imiquimod cream with that of placebo in the treatment of typical visible or palpable AK of the face or balding scalp. Subjects were scheduled for a total of 11 visits (1 prestudy screening visit and 10 on-study visits). Subjects determined to be eligible during the screening phase were randomized in a 1:1:1 ratio to 2.5% imiquimod cream, 3.75% imiquimod cream, or placebo cream. The creams were applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment. The investigator selected the treatment area for the study (either the entire face or the entire balding scalp, but not both). Subjects applied a thin layer of cream to the treatment area (up to 2 packets, or 500 mg of product, per application), avoiding the periocular areas, lips, and nares. Study medication was applied prior to normal sleeping hours and removed approximately 8 hours later with mild soap and water. Ears were excluded from both assessment and treatment. Rest periods from daily treatment were instituted by the investigator as needed to manage local skin reactions (LSRs) or application site reactions, with resumption of treatment upon adequate resolution as determined by the investigator.

The duration of each subject's study participation was approximately 21 weeks, including a 4-week maximum screening period and a 17-week study period. At the End of Study (EOS) visit, eligible subjects may have been invited to participate in a separate study evaluating AK recurrence.
Adequate measures to maintain ventilation and general circulatory support should be employed. Assisted or controlled ventilation, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Consideration should be given to gastric lavage and gastric aspiration to reduce drug absorption.

Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdosage or unusual sensitivity to pentazocine hydrochloride and acetaminophen tablets, parenteral naloxone is a specific and effective antagonist.

Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less then 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
The invention discloses recombinant avian flavivirus E protein and application thereof, which relate to the field of genetic engineering. The recombinant avian flavivirus E protein is obtained by gene cloning and expression technology. An indirect ELISA (enzyme-linked immuno sorbent assay) method which is established by using recombinant E protein as coating antigen is used for detecting avian flavivirus antibody. The method is the ELISA method, which constructs the ELISA method establishing detection, and recombinant avian virus E protein is initially and internationally used to construct and detect the avian flavivirus antibody. The method has the advantages of low cost, high specificity, high flexibility and the like. The recombinant avian flavivirus E protein can be used for determining specific antibody level of the avian flavivirus in a clinical domestic fowl, and natural infection. The invention further provides application of the recombinant avian flavivirus E protein to preparation of monoclonal antibody, polyclonal antibody, vaccines and protein chips.